Insights On Enterprise Solutions

  1. Streamlining Analytical Release Testing With Faster, Smaller Workflows 10/28/2025

    Reducing turnaround times and sample volumes in release testing can accelerate cell therapy manufacturing, preserve product yield, and improve patient outcomes.

  2. Advanced Sequencing Approaches For Comprehensive AAV Vector Characterization 10/28/2025

    Short and long read sequencing offer complementary insights into AAV vector identity, integrity, and impurity profiles, helping developers improve safety, efficacy, and scalability of gene therapy products.

  3. AAV-Based Gene Editing For Huntington's Disease 10/28/2025

    LETI-101 uses AAV5 to deliver a compact CRISPR system for allele-selective editing of mutant HTT, showing promise as a one-time treatment for Huntington’s disease with strong preclinical safety and efficacy.

  4. Onshoring Advantage: 7 Forces Reshaping Global Biologics Manufacturing 10/27/2025

    Policy, trade, and security pressures are fundamentally reshaping global biologics manufacturing. Forward-looking companies are onshoring critical programs to mitigate risks to supply chains, IP, and regulatory timelines.

  5. Smarter CMC Strategies To Accelerate Next-Gen Biologics To The Clinic 10/23/2025

    Learn how process design and cross-functional collaboration mitigate risks and accelerate the path from early development to FIH manufacturing through real-world case studies of practical approaches.

  6. Your Journey To GMP With Emphasis On Linker Payload Development 10/22/2025

    Develop lower-risk conjugation strategies by incorporating the critical insights we highlight in our review of semi-synthetic versus synthetic linker–payloads and their respective advantages and limitations.

  7. Custom Designed Linker-Payload Synthesis And Bioconjugation 10/22/2025

    Achieve ADC development with an integrated approach to linker-payload design and synthesis. Learn how custom synthesis and a bioconjugation strategy accelerate candidate selection and GMP manufacturing.

  8. Identification Of New Classes Of Maytansinoid Payloads For ADCs 10/22/2025

    See how a successful collaboration led to the design of novel, cell-permeable maytansine-based payloads for ADCs. These new tubulin inhibitors were engineered to enhance the critical "bystander killer effect."

  9. Essential Insights Into Linker Chemistry For ADCs 10/22/2025

    The linker is key to an ADC's success, influencing stability and targeted drug release. Explore the evolution of linker chemistry, from cleavable mechanisms to site-specific conjugation, and learn why rigorous assessment is critical.

  10. Optimizing CMC Strategy For Successful Scale-Up 10/22/2025

    In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) share advice on developing CMC strategies in a way that strengthens manufacturability through careful assay development and collaboration with CDMOs.